Low-Dose Tissue Plasminogen Activator Thrombolysis in Children
Open Access
- 1 May 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 25 (5) , 379-386
- https://doi.org/10.1097/00043426-200305000-00006
Abstract
To compare results of low-dose tissue plasminogen activator (TPA) in children with arterial and venous thrombi relative to standard published dosing. Subjects consisted of all consecutive children with objectively confirmed thrombi for whom TPA thrombolysis was clinically ordered by the authors. Initial dosing used published standard dose (0.1–0.5 mg/kg per hour). With experience, a low-dose regimen (0.01–0.06 mg/kg per hour) was given in an attempt to derive a minimal effective dose. Thirty-five children were treated with TPA. Either standard or low-dose infusions of TPA resulted in complete thrombolysis of 28 of 29 (97%) acute thrombi, while all 6 chronic thrombi had a partial response. In contrast to the recommended adult-derived dosages of 0.1 to 0.5 mg/kg per hour, the authors found that initial doses of less than 0.01 mg/kg per hour were effective in 12 of 17 patients with acute thrombosis. Neonates required 0.06 mg/kg per hour. Route of administration (local or systemic) did not affect efficacy. Major bleeding occurred in only one extremely preterm infant. Minor bleeding, primarily oozing at intravenous sites, occurred in 27% of children during TPA infusions. Prophylactic unfractionated or low-molecular-weight heparin was infused concomitant with TPA in 42% of the children and did not increase the risk of bleeding. TPA in very low doses appears to be safe and effective for thrombolysis of acute thromboses in most children, given appropriate patient selection.Keywords
This publication has 25 references indexed in Scilit:
- Outcome of Noncatheter-Related Thrombosis in Children: Influence of Underlying or Coexisting FactorsJournal of Pediatric Hematology/Oncology, 2001
- Outcome of Pediatric Thromboembolic Disease: A Report from the Canadian Childhood Thrombophilia RegistryPediatric Research, 2000
- Antithrombotic therapy in pediatrics: time for higher levels of evidence.The Journal of Pediatrics, 2000
- Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of Venous Thromboembolic ComplicationsThe Journal of Pediatrics, 1998
- Successful treatment of neonatal arterial thromboses with recombinant tissue plasminogen activatorThe Journal of Pediatrics, 1998
- Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTEBlood, 1994
- Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapyJournal of Pediatric Surgery, 1993
- Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusionThe Lancet, 1993
- Tissue plasminogen activator for the treatment of thromboembolism in infants and childrenThe Journal of Pediatrics, 1991
- Clot-Selective Coronary Thrombolysis with Tissue-Type Plasminogen ActivatorScience, 1983